Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of Pharvaris N.V. (NasdaqGS:PHVS) with a Overweight recommendation. Analyst Price Forecast Suggests 102.48% Upside As of ...

Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of InflaRx N.V. (NasdaqGS:IFRX) with a Overweight recommendation. Analyst Price Forecast Suggests 536.20% Upside As of ...

Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of BioCryst Pharmaceuticals (NasdaqGS:BCRX) with a Overweight recommendation. Analyst Price Forecast Suggests 86.43% ...

Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of Astria Therapeutics (NasdaqGM:ATXS) with a Overweight recommendation. Analyst Price Forecast Suggests 428.96% Upside ...

Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker ...

On Tuesday, Cantor Fitzgerald began coverage of Viking Therapeutics (NASDAQ:VKTX) shares, assigning an Overweight rating and setting a price target at $104.00. According to InvestingPro data, analyst ...

Financial markets have successfully navigated many significant economic disruptions in recent years and the current tariff disruption is likely to be no different. Picture: Getty ...

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (LSE:0VQA) with a Overweight recommendation. There are 777 funds or institutions reporting ...